Communiqués Sandoz Group AG

Actions

SDZ

CH1243598427

Marché Fermé - Swiss Exchange Autres places de cotation 17:30:41 31/05/2024			Varia. 5j.	Varia. 1 janv.
32,06 ^CHF	+1,04 %		+0,12 %	+18,48 %

24/05	Wall Street se prend un petit coup de tatane
24/05	AVIS D'ANALYSTES DU JOUR : Renault, Legrand, Orange, Nexans, Soitec, Julius Bär, Wizz Air...

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Fresenius Kabi Announces FDA Acceptance Of ABLA For Prolia® / Xgeva® (Denosumab) Biosimilar Candidate FKS518	31/05	AQ
Sandoz receives European Commission approval for Wyost and Jubbonti, the first and only biosimilars of denosumab in Europe	23/05	AQ
European Commission grants first-of-a-kind biosimilar approval	22/05	AQ
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe	22/05	GL
Sandoz reports first quarter 2024 sales	07/05	GL
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG	30/04	GL
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars	30/04	GL
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering	22/04	GL
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines	21/03	GL
Sandoz reports fourth quarter 2023 sales and full-year 2023 results	13/03	GL
Sandoz reports fourth quarter 2023 sales and full-year 2023 results	13/03	AQ
Sandoz receives FDA approval for first and only denosumab biosimilars	05/03	GL
Sandoz announces nominations to the Board of Directors and leadership change	05/03	GL
Sandoz announces nominations to the Board of Directors and leadership change	05/03	AQ
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market	04/03	GL
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market	04/03	AQ
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs	29/02	GL
Sandoz announces changes in the Board of Directors	01/02	GL
Sandoz announces changes in the Board of Directors	01/02	AQ
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany	31/01	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

SANDOZ : Les améliorations de Sandoz valent la peine d'être pariées

Le 08 mai 2024 à 14:08